Cardiometabolic Disorders News

Genetic predisposition to denture use was associated with increased likelihood of cardiometabolic diseases and related risk factors including dyslipidemia and elevated waist circumference, researchers reported.

Diagnostic testing for hypertension, diabetes and hypercholesterolemia remains low globally, driven by substantial shares of low- and middle-income populations who are not tested despite meeting WHO criteria.

Physical activity during the morning and afternoon, but not during the evening, is associated with a lower risk for developing type 2 diabetes, according to findings published in Diabetologia.

With reports of dramatic weight loss achieved using a new generation of diabetes drugs — one FDA approved for weight loss and another with a decision expected this fall — more adults are seeking medical therapy for obesity.

Menstrual cycle irregularity and age at menarche were significantly associated with parameters of cardiometabolic health in early adulthood among a mostly Black cohort of young women, researchers reported.

An analysis of 22 produce prescription programs throughout the U.S. suggests that the interventions improve fruit and vegetable intake, reduce food insecurity and are tied to clinically significant gains in cardiometabolic health measures.

The fully monoclonal angiopoietin-like 3 antibody evinacumab conferred sustained, long-term reductions in LDL and other atherogenic lipoproteins among patients with refractory hyperlipidemia, researchers reported.

All-cause and cardiovascular mortality rates remained flat from 2006 to 2020 for people with type 1 diabetes who had a first-time myocardial infarction, despite mortality rates declining for type 2 diabetes, according to two presenters.

An investigational aldosterone synthase inhibitor was associated with clinically significant reductions in automated office BP for people with uncontrolled hypertension, with the greatest effects seen in people with concomitant obesity.

Monthly lerodalcibep on top of maximum tolerated therapy reduced LDL an additional 60% over 24 weeks in patients with heterozygous familial hypercholesterolemia, with a safety profile similar vs. placebo, a speaker reported.